Jeremy Caudill is the Founder and CEO for Ninnion® Therapeutics, a CNS pharmaceutical company in Austin, Texas focused on using AI drug discovery to develop next-generation psychedelic drug candidates designed for Rx payer reimbursement. A successful entrepreneur and executive with over 25 years of experience in the pharmaceutical industry, Jeremy’s path to founding Ninnion began when he was diagnosed with a life-threatening aortic aneurysm and heart valve defect that required emergency open heart surgery in 2017. During his recovery from surgery, he suffered an ischemic stroke after 9 weeks and then a second double stroke in both brain hemispheres 6 months later. Determined to get his life back, he began searching for scientific studies on neuroplasticity, neurogenesis, and the general mechanisms of healing the brain. He came across the promising psychedelics research at Johns Hopkins, MAPS, Compass, and Usona. Jeremy saw a lecture by Dr. James Fadiman who described the great potential for serotonergic psychedelics in low doses multiple times per week as a kind of “miracle grow for the brain”. This is based on the potential to stimulate the growth of new brain cells as well as the very important neuroplastic effects in the brain which are essential for overcoming stroke deficits by retraining different parts of the brain and restore function during occupational, speech, and physical therapy . Encouraged by the scientific literature, Jeremy began to incorporate micro dosing to great effect into his own recovery. There are no drugs currently approved by the FDA for stroke recovery making this an area of high unmet need for these patients. So, with his knowledge, experience, and network in the pharmaceutical industry, Jeremy decided to dedicate this new chapter of his life and form a company focused on bringing psychedelic medicines safely and responsibly through clinical trials and gain FDA approvals, so that others could benefit. Dr. Rick Strassman agreed to help Jeremy and joined his SAB when he founded the Ninnion in late November 2020 and the company is now preparing its proprietary NIN-S119 (psilocin-like) molecule for human clinical trials to help stroke patients restore their lives.